Pharmacovigilance and Reporting Adverse Drug Reactions

Pharmacovigilance and Reporting Adverse Drug Reactions

Dr. Isa Naina Mohamed, Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Tel: +603-91459545Fax: +6-03-91459547 Email: isanaina@ppukm.ukm.edu.my

Beijer, H.J., Blaey, C.J. 2002. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24(2): 46-54. Buajordet, I., Ebbesen, J., Erikssen, J., Brors, O., Hilberg, T. 2001. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4): 327-341. Bulletin MADRAC. 2014. http://portal.bpfk.gov.my/index.cfm?&menuid=149&parentid=17 [12 December 2014] British Medical Association. 2006. A guide for healthcare professionals. Reporting adverse drug reactions. London. http://www.isoponline.org/documents/news/BMAreport.pdf[12 December2014] Clarkson, A., Choonara, I. 2002. Surveillance for fetal suspected adverse drug reactions in the UK. Arch Dis Child 87(6): 462-466. Davies, E.C., Green, C.F., Mottram, D.R., Pirmohamed, M. 2006. Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 31(4): 335-341. Edwards, I.R., Aronson, J.K. 2000. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237): 1255-1259. Food and Drug Administration. 2005. Guidance for Industry-Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. US: FDA. Goettler, M., Schneeweiss, S., Hasford, J. 1997. Adverse drug reaction monitoring--Cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 6(suppl 3): S79-S90. Hazell, L., Shakir, S.A. 2006. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5): 385-396. Impicciatore, P., Choonara, I., Clarkson, A., Provasi, D., Pandolfini, C., Bonati, M. 2001. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1): 77-83. Jeffreys, D.B., Leakey, D., Lewis, J.A., Payne, S., Rawlins, M.D. 1998. New active substance authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 45(2): 151-156. Lazarou, J., Pomeranz, B.H., Corey, P.N. 1998. Incidence of adverse drug reactions in hospitalized patients. JAMA 279(15): 1200-1205. Le, J., Nguyen, T., Law, A.V., Hodding, J. 2006. Adverse drug reactions among children over a 10-year period. Paediatrics 118(2): 555-562. Malaysian Adverse Drug Reactions Advisory Committe (MADRAC). 2012.http://portal.bpfk.gov.my/index.cfm?&menuid=24&parentid=16 [12 December 2014] Martys, C.R. 1979. Adverse reactions to drugs in general practice. Br Med J 2(6199): 1194-1197. Medicines and Healthcare products Regulatory Agency (MHRA). 2013. Medicines for children. http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesforchildren/CON009648 [14 December 2014] Medicines and Healthcare Products Regulatory Agency (MHRA). 2014. Yellow Card data. Trends in UK spontaneous Adverse Drug Reaction (ADR) reporting between 2008-2012. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/ [12 December 2014] Meyboom, R.H., Egberts, A.C., Gribnau, F.W., Hekster, Y.A. 1999. Pharmacovigilance in perspective. Drug Saf 21(6): 429-447. Meyboom, R.H., Lindquist, M., Egberts, A.C. 2000. An ABC of drug-related problems. Drug Saf 22(6): 415-423. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K., Breckenridge, A.M. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456): 15-19. Pirmohamed, M. 2005. Anticipating, investigating and managing the adverse effects of drugs. Clin Med 5(1): 23-25. Pouyanne, P., Haramburu, F., Imbs, J.L., Begaud, B. 2000. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 320(7241): 1036. Routledge, P. 1998. 150 years of pharmacovigilance. Lancet 351(9110): 1200-1201. Strom, B.L. 2006. Pharmacoepidemiology, 4th edition. Edited by Strom BL. Chichester, UK: John Wiley & Sons, Ltd; 35 102 Med & Health 2014; 9(2): 92-102 Isa N.M. Uppsala Monitoring Centre. 2000. Guidelines for setting up and running a Pharmacovigilance Centre. Safety Monitoring of Medicinal Products. Uppsala, Sweden: UMC.http://apps.who.int/medicinedocs/en/d/Jh2934e/1.html [14 December 2014] Uppsala Monitoring Centre. http://www.who-umc.org/ [12 December 2014) Walley, T. 1995. Drugs, money and society. Br J Clin Pharmacol 39(4): 343-345. World Health Organization. 2002a. Safety monitoring of medicinal products. The importance of pharmacovigilance. Geneva: WHO. http://apps.who.int/medicinedocs/en/d/Js4893e/10.html [14 December 2014]. World Health Organization. 2002b. Safety of Medicines - A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva: WHO. http://apps.who.int/medicinedocs/en/d/Jh2992e/ [14 December 2014] World Health Organization. 2004. Countries At The Core 2004-2007. Medicines Strategy. Geneva: WHO. http://apps.who.int/medicinedocs/en/d/Js5416e/ [14 December 2014]